Attention-deficit/hyperactivity disorder, oppositional defiant disorder, and conduct disorder

Psychiatric Annals

Volumn 33, Issue 4, 2003, Pages 245-252

  Althoff, Robert R ^a   Rettew, David C ^b   Hudziak, James J ^a,b  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; CARBAMAZEPINE; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; GUANFACINE; IMIPRAMINE; LITHIUM CARBONATE; METHYLIN; METHYLIN ER; METHYLPHENIDATE; NEUROLEPTIC AGENT; NICOTINE; PEMOLINE; PEMOLINE MAGNESIUM; PROPRANOLOL; PSYCHOSTIMULANT AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; WELLBUTRIN SR;

AGGRESSION; ANXIETY DISORDER; APPETITE DISORDER; ATRIOVENTRICULAR BLOCK; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; BRADYCARDIA; BULIMIA; CHILD PSYCHIATRY; COMORBIDITY; CONDUCT DISORDER; CONSTIPATION; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE PREDISPOSITION; DOPAMINE TRANSPORTER GENE; DRUG DEPENDENCE; GENE; GENETICS; GROWTH RETARDATION; HEADACHE; HEART ARRHYTHMIA; HEART DEATH; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; LIVER FAILURE; NAUSEA; NEUROBIOLOGY; NONHUMAN; OPPOSITIONAL DEFIANT DISORDER; REBOUND; REVIEW; SUBSTANCE ABUSE; TACHYCARDIA; TREATMENT CONTRAINDICATION; WEIGHT GAIN; XEROSTOMIA;

EID: 1942531616     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20030401-05     Document Type: Review

References (50)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th ed Washington, DC: American Psychiatric Association; 1994.
2. Still GF. Some abnormal psychical conditions in children. Lancet. 1902;1:1008-1012, 1077-1082, 1163-1168.
3. Jensen P, Martin C, Cantwell D. Comorbidity in ADHD: implications for research, practice and DSM-IV. J Am Acad Child Adolesc Psychiatry. 1997;36:1065-1079.
4. Jensen PS, members of the MTA Cooperative Group. ADHD comorbidity findings from the MTA study. In: Helzer JE, Hudziak JJ, eds. Defining Psychopathology in the 21st Century: DSM-V and Beyond. Washington, DC: American Psychopathological Association; 2002:169-192.
5. Hudziak JJ. The role of phenotypes (diagnoses) in genetic studies of attention-deficit/hyperactivity disorder and related child psychopathology. Child Adolesc Psychiatr Clin N Am. 2000;10:279-297.
6. Conners CK, Wells KC, Parker JD, Sitarenios G, Diamond JM, Powell JW. A new self-report scale for assessment of adolescent psychopathology: factor structure, reliability, validity, and diagnostic sensitivity. J Abnorm Child Psychol. 1997;25:487-497.
7. Brown TE. Brown Attention-Deficit Disorder Scales®. San Antonio, Tex: Psychological Corp/Harcourt Brace Jovanovich; 1996.
8. Swanson JM, Wigal S, Greenhill LL, et al. Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry. 1998;37:519-526.
9. Faraone SV, Biederman J, Mick E, et al. A family study of psychiatric comorbidity in girls and boys with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2001;50:586-592.
10. Offord D, Boyle M, Szatmari P, et al. Ontario Child Health Study. Six-month prevalence of disorder and rates of service utilization. Arch Gen Psychiatry. 1987;44:832-836.
11. Woodward LJ, Fergusson DM, Horwood LJ. Driving outcomes of young people with attentional difficulties in adolescence. J Am Acad Child Adolesc Psychiatry. 2000;39:627-634.
12. Barkley R, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics. 1996;98(6 Pt 1):1089-1095.
13. Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis. 1997;185:475-482.
14. Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O'Brien PC. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA. 2001;285:60-66.
15. Swanson J, Costellanos FX, Murias M, et al. Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Curr Opin Neurobiol. 1998;8:263-271.
16. Barkley RA. ADHD and the Nature of Self Control. New York, NY: Guilford; 1997.
17. Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry. 1998;44:951-958.
18. Loeber R, Burke JD, Lahey BB, et al. Oppositional defiant and conduct disorder: a review of the past 10 years, part I. J Am Acad Child Adolesc Psychiatry. 2000;39:1468-1484.
19. Kazdin AE. Treatment of Antisocial Behavior in Children and Adolescents. Homewood, III: Dorsey; 1985.
20. Kruesi MJ, Rapoport JL, Hamburger S, et al. Cerebrospinal fluid monoamine metabolites, aggression, and impulsivity in disruptive behavior disorders of children and adolescents. Arch Gen Psychiatry. 1990;47:419-426.
21. Caspi A, McClay J, Moffitt TE, et al. Role of genotype in the cycle of violence in maltreated children. Science. 2002;297:851-854.
22. Morell V. Evidence found for a possible 'aggression gene.' Science. 1993;260:1722-1723.
23. Hudziak JJ, Todd RD. Familial subtyping attention deficit hyperactivity disorder. Current Opinion in Psychiatry. 1993;6:489-493.
24. Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2000;9:77-97.
25. National Prescription Audit and National Prescription Audit Plus. Plymouth Meeting, Pa: IMS Health; 1982-2000.
26. Spencer T, Biederman J, Wilens T, Prince J. Pharmacotherapy of attention-deficit/hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35:1460-1467.
27. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(suppl 2):26S-49S.
28. Wilens TE, Biederman J, Baldessarini RJ, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1996;35:1491-1501.
29. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry. 1989;28:777-784.
30. Prince JB, Wilens TE, Biederman J, et al. A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2000;10:193-204.
31. Popper CW. Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2000;9:605-646.
32. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:649-657.
33. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001;158:282-288.
34. Olvera RL, Pliszka SR, Luh J, Tatum R. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol. 1996;6:241-250.
35. Hunt RD, Capper L, O'Connell P. Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol. 1990;1:87-102.
36. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:50-54.
37. Green WH. Child and Adolescent Clinical Psychopharmacology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001.
38. Wilens TE, Spencer TJ, Swanson JM, et al. Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry. 1999;38:614-622.
39. Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH. Psychopharmacology and aggression. I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41:253-261.
40. Kolko DJ, Bukstein OG, Barron J. Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. J Am Acad Child Adolesc Psychiatry. 1999;38:578-586.
41. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila). 2000;39:15-25.
42. Steiner H. Practice parameters for the assessment and treatment of children and adolescents with conduct disorder. J Am Acad Child Adolesc Psychiatry. 1997;36(suppl 10):122S-139S.
43. Campbell M, Gonzalez NM, Silva RR. The pharmacologic treatment of conduct disorders and rage outbursts. Psychiatr Clin North Am. 1992;15:69-85.
44. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159:1337-1346.
45. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314-321.
46. Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol. 1993;3:1-10.
47. Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry. 2001;40:307-314.
48. Disney ER, Elkins IJ, McGue M, Iacono WG. Effects of ADHD, conduct disorder, and gender on substance use and abuse in adolescence. Am J Psychiatry. 1999;156:1515-1521.
49. Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 1999;104(2):e20.
50. Riggs PD, Leon SL, Mikulich SK, Pottle LC. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry. 1998;37:1271-1278.